Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers

Jenette Creaney; Ian Dick; Arthur W.(. Musk; Nola J. Olsen; Bruce W.S. Robinson

doi:10.3109/1354750X.2016.1160429

Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers

Jenette Creaney, Ian Dick, Arthur W.(. Musk, Nola J. Olsen, Bruce W.S. Robinson

School of Population and Global Health

Research output: Contribution to journal › Article › peer-review

6 Citations (Web of Science)

Abstract

© 2016 Informa UK Limited, trading as Taylor & Francis Group.The asbestos induced cancer malignant mesothelioma (MM) is difficult to diagnose and has a poor prognosis. MM is an immunological cancer, therefore autoantibodies may be suitable biomarkers and associated with prognosis. We used Protoarray® microarrays to determine immune responses to 8798 antigens in 10 MM and 10 asbestos exposed controls and developed diagnostic panels using 17 antigens from this. The AUC of these panels were independently tested in these 10 MM patients and controls and in a validation group of 36 controls and 35 MM patients using luminex assays; none of the antigens identified were validated. Immune responses to RAB38 were associated with a better prognosis.

Original language	English
Pages (from-to)	551-561
Number of pages	11
Journal	Biomarkers
Volume	21
Issue number	6
DOIs	https://doi.org/10.3109/1354750X.2016.1160429
Publication status	Published - 17 Aug 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/1354750X.2016.1160429

Cite this

@article{96badaff15f748199e85a54e24c68712,

title = "Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers",

abstract = "{\textcopyright} 2016 Informa UK Limited, trading as Taylor & Francis Group.The asbestos induced cancer malignant mesothelioma (MM) is difficult to diagnose and has a poor prognosis. MM is an immunological cancer, therefore autoantibodies may be suitable biomarkers and associated with prognosis. We used Protoarray{\textregistered} microarrays to determine immune responses to 8798 antigens in 10 MM and 10 asbestos exposed controls and developed diagnostic panels using 17 antigens from this. The AUC of these panels were independently tested in these 10 MM patients and controls and in a validation group of 36 controls and 35 MM patients using luminex assays; none of the antigens identified were validated. Immune responses to RAB38 were associated with a better prognosis.",

author = "Jenette Creaney and Ian Dick and Musk, {Arthur W.(.} and Olsen, {Nola J.} and Robinson, {Bruce W.S.}",

year = "2016",

month = aug,

day = "17",

doi = "10.3109/1354750X.2016.1160429",

language = "English",

volume = "21",

pages = "551--561",

journal = "Biomarkers",

issn = "1354-750X",

publisher = "Informa Healthcare USA",

number = "6",

}

TY - JOUR

T1 - Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers

AU - Creaney, Jenette

AU - Dick, Ian

AU - Musk, Arthur W.(.

AU - Olsen, Nola J.

AU - Robinson, Bruce W.S.

PY - 2016/8/17

Y1 - 2016/8/17

N2 - © 2016 Informa UK Limited, trading as Taylor & Francis Group.The asbestos induced cancer malignant mesothelioma (MM) is difficult to diagnose and has a poor prognosis. MM is an immunological cancer, therefore autoantibodies may be suitable biomarkers and associated with prognosis. We used Protoarray® microarrays to determine immune responses to 8798 antigens in 10 MM and 10 asbestos exposed controls and developed diagnostic panels using 17 antigens from this. The AUC of these panels were independently tested in these 10 MM patients and controls and in a validation group of 36 controls and 35 MM patients using luminex assays; none of the antigens identified were validated. Immune responses to RAB38 were associated with a better prognosis.

AB - © 2016 Informa UK Limited, trading as Taylor & Francis Group.The asbestos induced cancer malignant mesothelioma (MM) is difficult to diagnose and has a poor prognosis. MM is an immunological cancer, therefore autoantibodies may be suitable biomarkers and associated with prognosis. We used Protoarray® microarrays to determine immune responses to 8798 antigens in 10 MM and 10 asbestos exposed controls and developed diagnostic panels using 17 antigens from this. The AUC of these panels were independently tested in these 10 MM patients and controls and in a validation group of 36 controls and 35 MM patients using luminex assays; none of the antigens identified were validated. Immune responses to RAB38 were associated with a better prognosis.

U2 - 10.3109/1354750X.2016.1160429

DO - 10.3109/1354750X.2016.1160429

M3 - Article

C2 - 27009350

SN - 1354-750X

VL - 21

SP - 551

EP - 561

JO - Biomarkers

JF - Biomarkers

IS - 6

ER -

Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this